Guangdong Taiantang Pharmaceutical
Launch date
Employees
Market cap
$28.5m
Enterprise valuation
$187m (Public information from Jul 2024)
Share price
CNY0.27 002433.SZ
Shantou Guangdong (HQ)
Financials
Estimates*
| CNY | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 4.0b | 3.6b | 2.3b | 725m | 410m |
| % growth | - | - | - | (11 %) | (37 %) | (68 %) | (43 %) |
| EBITDA | - | - | 374m | 291m | (<1m) | 58.9m | (313m) |
| % EBITDA margin | - | - | 9 % | 8 % | - | 8 % | (76 %) |
| Profit | - | - | 96.1m | 22.2m | (803m) | (823m) | (2.2b) |
| % profit margin | - | - | 2 % | 1 % | (35 %) | (114 %) | (539 %) |
| EV / revenue | - | - | 1.4x | 1.6x | 3.2x | 6.5x | 7.2x |
| EV / EBITDA | - | - | 14.8x | 19.1x | -27489.8x | 79.5x | -9.4x |
| R&D budget | - | - | 24.3m | 20.4m | 30.4m | 26.7m | 7.5m |
| R&D % of revenue | - | - | 1 % | 1 % | 1 % | 4 % | 2 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
